Department of Health Services, Policy and Practice and Center for Gerontology and Health Care Research, Brown University, Providence, RI; Optum Epidemiology, Boston, MA.
Department of Health Services, Policy and Practice and Center for Gerontology and Health Care Research, Brown University, Providence, RI.
J Am Med Dir Assoc. 2018 Apr;19(4):328-332.e2. doi: 10.1016/j.jamda.2017.09.015. Epub 2017 Nov 7.
The Food and Drug Administration recommends a reduced dose of nonbenzodiazepine hypnotics in women, yet little is known about the age-, sex-, and dose-specific effects of these drugs on risk of hip fracture, especially among nursing home (NH) residents. We estimated the age-, sex-, and dose-specific effects of nonbenzodiazepine hypnotics on the rate of hip fracture among NH residents.
Case-crossover study in US NHs.
A total of 691 women and 179 men with hip fracture sampled from all US long-stay NH residents.
Measures of patient characteristics were obtained from linked Medicare and the Minimum Data Set (2007-2008). The outcome was hospitalization for hip fracture with surgical repair. We estimated rate ratios (RRs) and 95% confidence intervals (CIs) from conditional logistic regression models for nonbenzodiazepine hypnotics (vs nonuse) comparing 0 to 29 days before hip fracture (hazard period) with 60 to 89 and 120 to 149 days before hip fracture (control periods). We stratified analyses by age, sex, and dose.
The average RR of hip fracture was 1.7 (95% CI 1.5-1.9) for any use. The RR of hip fracture was higher for residents aged ≥90 years vs <70 years (2.2 vs 1.3); however, the CIs overlapped. No differences in the effect of the hypnotic on risk of hip fracture were evident by sex. Point estimates for hip fracture were greater with high-dose versus low-dose hypnotics (RR 1.9 vs 1.6 for any use), but these differences were highly compatible with chance.
The rate of hip fracture in NH residents due to use of nonbenzodiazepine hypnotics was greater among older patients than among younger patients and, possibly, with higher doses than with lower doses. When clinicians are prescribing a nonbenzodiazepine hypnotic to any NH resident, doses of these drugs should be kept as low as possible, especially among those with advanced age.
美国食品和药物管理局建议减少非苯二氮䓬类催眠药在女性中的剂量,但对于这些药物在髋部骨折风险方面的年龄、性别和剂量特异性影响知之甚少,尤其是在养老院(NH)居民中。我们评估了非苯二氮䓬类催眠药在 NH 居民中髋部骨折发生率方面的年龄、性别和剂量特异性影响。
美国 NH 中的病例交叉研究。
从所有美国长期 NH 居民中抽取了 691 名女性和 179 名男性髋部骨折患者。
从链接的医疗保险和最小数据集中获取患者特征测量值(2007-2008 年)。结果是住院治疗髋部骨折并接受手术修复。我们从条件逻辑回归模型中估计了非苯二氮䓬类催眠药(与未使用相比)的率比(RR)和 95%置信区间(CI),比较了髋部骨折前 0 至 29 天(危险期)与髋部骨折前 60 至 89 天和 120 至 149 天(对照期)。我们按年龄、性别和剂量进行分层分析。
任何使用非苯二氮䓬类催眠药的髋部骨折 RR 平均为 1.7(95%CI 1.5-1.9)。与年龄<70 岁的居民相比,年龄≥90 岁的居民髋部骨折的 RR 更高(2.2 比 1.3);然而,CI 重叠。催眠药对髋部骨折风险的影响在性别方面没有差异。高剂量与低剂量催眠药相比,髋部骨折的点估计值更大(任何使用的 RR 为 1.9 比 1.6),但这些差异极有可能是偶然的。
NH 居民因使用非苯二氮䓬类催眠药导致髋部骨折的发生率在年龄较大的患者中高于年龄较小的患者,并且可能与较高剂量而非较低剂量有关。当临床医生为任何 NH 居民开非苯二氮䓬类催眠药时,这些药物的剂量应尽可能低,尤其是在年龄较大的患者中。